Exact Mass: 413.2137

Exact Mass Matches: 413.2137

Found 42 metabolites which its exact mass value is equals to given mass value 413.2137, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

(Z)-7-[(1R,2R,3R,4S)-3-[(E)-C-Methyl-N-(phenylcarbamothioylamino)carbonimidoyl]-2-bicyclo[2.2.1]heptanyl]hept-5-enoic acid

C23H31N3O2S (413.2137)

Heliosupine N-oxide

[(7S,8R)-7-[(Z)-2-methylbut-2-enoyl]oxy-4-oxido-5,6,7,8-tetrahydro-3H-pyrrolizin-4-ium-1-yl]methyl (2R)-2,3-dihydroxy-2-[(1S)-1-hydroxyethyl]-3-methylbutanoate

C20H31NO8 (413.205)

Echimidine N-oxide

Echimidine N-oxide5,7-Diacetoxy-8-methoxyflavoneMurraolNortanshinonePolyphyllin C(-)-IntegerrimineTenacissoside IRosthornin Bp-Hydroxyphenethyl anisateMomordicoside KTremulacinQuinine hemisulfate hydrateIlexsaponin A

C20H31NO8 (413.205)

Echimidine N-oxide

C20H31NO8 (413.205)

CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2305

Delanzomib

CEP-18770 (Delanzomib)

C21H28BN3O5 (413.2122)

D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D061988 - Proteasome Inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2160 - Proteasome Inhibitor C471 - Enzyme Inhibitor

(S)-4-((10,12-DIOXO-12-((2-OXOTETRAHYDROFURAN-3-YL)AMINO)DODECYL)OXY)-4-OXOBUTANOIC ACID

C20H31NO8 (413.205)

N-trifluoroacetyl (TFA)

C17H31F3N3O3P (413.2055)

Spiro[2H-indole-2,3-[3H]naphth[2,1-b][1,4]oxazine], 1,3-dihydro-1,3,3-triMethyl-6-(4-Morpholinyl)-

C26H27N3O2 (413.2103)

Butyl 4-(4-ethoxy-3-methoxyphenyl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate

C24H31NO5 (413.2202)

(E)-7-[3-[(E)-C-methyl-N-(phenylcarbamothioylamino)carbonimidoyl]norbornan-2-yl]hept-5-enoic acid

C23H31N3O2S (413.2137)

3-(2-Hydroxy-4,6-dimethoxyphenyl)-3-(4-methoxyphenyl)-1-(3-methyl-1-piperidinyl)-1-propanone

C24H31NO5 (413.2202)

2-(4-benzoyl-1-piperazinyl)-N-(2-phenylphenyl)propanamide

C26H27N3O2 (413.2103)

2-[4-(9H-fluoren-9-yl)-1-piperazinyl]-N-(4-methoxyphenyl)acetamide

C26H27N3O2 (413.2103)

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide

C21H27N5O4 (413.2063)

N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide

C21H27N5O4 (413.2063)

N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide

C21H27N5O4 (413.2063)

N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide

C21H27N5O4 (413.2063)

N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide

C21H27N5O4 (413.2063)

N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide

C21H27N5O4 (413.2063)

N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide

C21H27N5O4 (413.2063)

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide

C21H27N5O4 (413.2063)

N,N-dimethyl-4-[4-[(1S,5R)-3-(5-pyrimidinylmethyl)-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzamide

C25H27N5O (413.2215)

(1R,5S)-N-(2-methoxyphenyl)-7-[4-(2-methylphenyl)phenyl]-3,6-diazabicyclo[3.1.1]heptane-6-carboxamide

C26H27N3O2 (413.2103)

[(4R,7R,8R)-7-[(Z)-2-methylbut-2-enoyl]oxy-4-oxido-5,6,7,8-tetrahydro-3H-pyrrolizin-4-ium-1-yl]methyl (2R)-2,3-dihydroxy-2-[(1S)-1-hydroxyethyl]-3-methylbutanoate

C20H31NO8 (413.205)

ST 18:1;O6;Gly

C20H31NO8 (413.205)

ST 22:5;O3;Gly

C24H31NO5 (413.2202)

ST 19:1;O2;Tau

C21H35NO5S (413.2236)

KRAS inhibitor-3

C25H27N5O (413.2215)

KRAS inhibitor-3 is an inhibitor of KRAS inhibitor. KRAS inhibitor-3 binds to WT and oncogenic KRAS mutants with high affinity (KD: 0.28 μM for KRAS WT, 0.63 μM for KRAS G12C, 0.37 μM for KRAS G12D, 0.74 μM for KRAS Q61H). KRAS inhibitor-3 also disrupts interaction of KRAS with Raf[1].

(7r,7ar)-1-({[(2r)-2,3-dihydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-7-{[(2z)-2-methylbut-2-enoyl]oxy}-5,6,7,7a-tetrahydro-3h-pyrrolizin-4-ium-4-olate

C20H31NO8 (413.205)

1-({[2,3-dihydroxy-2-(1-hydroxyethyl)-3-methylbutanoyl]oxy}methyl)-7-[(2-methylbut-2-enoyl)oxy]-5,6,7,7a-tetrahydro-3h-pyrrolizin-4-ium-4-olate

C20H31NO8 (413.205)